ATC Group: L01FB02 Moxetumomab pasudotox

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FB02 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FB CD22 (Clusters of Differentiation 22) inhibitors
5 L01FB02 Moxetumomab pasudotox

Related product monographs

Document Type Information Source  
 LUMOXITI Powder for concentrate solution for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 LUMOXITI Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Brazil (BR)

Estonia (EE)

Lithuania (LT)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.